Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Cameron’s Law
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Cameron’s Law
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · third_quarter · Q3
Rare Disease Initiatives. Priority Review Voucher Reauthorization. Newborn Screening.
Pharmaceutical issues impacting patients with rare diseases. Prescription Drug User Fee Act (PDUFA) Reauthorization. PRV Reauthorization. Promising Pathways Act 2.0. Public Law 119-21: One Big Beautiful Bill Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Cameron’s Law
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Innovation in Pediatric Drugs Act of 2025
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · second_quarter · 2A
Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Priority Review Voucher Reauthorization. Newborn Screening.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations. Advanced Research Projects Agency - Health (ARPA-H) Appropriations. NIH / FDA Appropriations. HHS RIFs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · second_quarter · Q2
Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Priority Review Voucher Reauthorization. Newborn Screening.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations. Advanced Research Projects Agency - Health (ARPA-H) Appropriations. NIH / FDA Appropriations. HHS RIFs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · first_quarter · Q1
Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. Priority Review Voucher Reauthorization. Accelerated Approval. Newborn Screening.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE